FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/080065 [Registered on: 07/02/2025] Trial Registered Prospectively
Last Modified On: 05/02/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Biological 
Study Design  Randomized, Parallel Group, Multiple Arm Trial 
Public Title of Study   Trial of Immuno modulatory drugs in TBM 
Scientific Title of Study   Randomized Trial of Thalidomide and Infliximab in Paradoxical Worsening in Patients of Tuberculous Meningitis (TBM): A Clinical, Radiological and Biomarker based Study 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Manish Modi 
Designation  Professor 
Affiliation  PGIMER 
Address  Deapartment of Neurology, PGIMER, Sector 12, CHANDIGARH
SECTOR 12, CHANDIGARH
Chandigarh
CHANDIGARH
160012
India 
Phone  9876197533  
Fax  01722744401  
Email  modipgi@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Manish Modi 
Designation  Professor 
Affiliation  PGIMER 
Address  Deapartment of Neurology, PGIMER, Sector 12, CHANDIGARH
SECTOR 12, CHANDIGARH
Chandigarh
CHANDIGARH
160012
India 
Phone  9876197533  
Fax  01722744401  
Email  modipgi@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Manish Modi 
Designation  Professor 
Affiliation  PGIMER 
Address  Deapartment of Neurology, PGIMER, Sector 12, CHANDIGARH
SECTOR 12, CHANDIGARH
Chandigarh
CHANDIGARH
160012
India 
Phone  9876197533  
Fax  01722744401  
Email  modipgi@gmail.com  
 
Source of Monetary or Material Support  
ICMR, V. Ramalingaswami Bhawan, P.O. Box No. 4911 Ansari Nagar, New Delhi - 110029, India 
 
Primary Sponsor  
Name  ICMR New Delhi INDIA 
Address  V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi - 110029, India 
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Manish Modi  PGIMER, CHANDIGARH, INDIA  Department of Neurology, Ground Floor, A Block, Room no. 7, Nehru Hospital Building, PGIMER, Chandigarh-160012, INDIA
Chandigarh
CHANDIGARH 
9876197533

modipgi@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, PGIMER, Chandigarh  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: A179||Tuberculosis of nervous system, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Infliximab  Infliximab will be given intravenously as infusion in a dose of 5mg/kg/ month for 3-6 months  
Intervention  Thalidomide  Thalidomide will be given orally in a dose of 3mg/kg body weight per day for 3 months and then gradually tapered off over 3 months 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1. Age 18 years or more
2. Confirmed cases of CNS TB with Paradoxical response based on clinical, biochemical (CSF) and radiological imaging.
3. Willingness to participate in the study.
 
 
ExclusionCriteria 
Details  1. Patients less than 18 years
2. Patients having MDR TB.
3. Patients in whom the symptoms were better explained by some other cause as per abnormalities in the investigations performed
4. Patients not willing to give written informed consent or Assent
5. Other similar diseases mimicking TBM like fungal infections, etc.
6. Pregnancy
7. Patients with HIV 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Other 
Blinding/Masking   Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
To study the clinical outcome in patients of CNS TB with paradoxical response  Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
1. To study the radiological outcome on follow up along with clinical parameters  At end of 3 months, 6 months and completion of therapy 
2. To study cytokine levels in CSF and Blood at time of recruitment and Changes in blood on follow up after 3 months  At Baseline and at 3 months 
 
Target Sample Size   Total Sample Size="198"
Sample Size from India="198" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3/ Phase 4 
Date of First Enrollment (India)   20/02/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Patients with Diagnosed Tuberculous Meningitis can paradoxically worsen after starting Antitubercular Treatment (ATT) and steroids. Paradoxical worsening manifests as vision loss, myelopathy, cranial nerve deficits, and hydrocephalus, due to arachnoiditis. We are proposing TBM as both a paucibacillary infectious and Immunological disorder, which needs stronger immunomodulation in patients with paradoxical responses.

With this background, all patients who fulfill Marais’s criteria for TBM, already being followed up every month in the TBM Clinic of PGIMER, Chandigarh will be assessed for paradoxical worsening. After confirming radiologically, these patients will be subjected to CSF analysis to rule out MDR TB or alternate infections and assess cytokine levels in CSF and serum. All the cases will be evaluated independently by 2 Neurologists with experience in Neuro infections and 1 infectious disease expert. Diagnosis of paradoxical worsening will be reached by consensus. Thereafter, these patients will be randomized to Thalidomide or Infliximab arm vs standard care (Steroids). All patients will be followed up monthly for any complications till the completion of therapy. However, repeat radiological, and biomarkers (TNF alpha, VEGF, IL-6, and IL-10) responses will be measured at 3 months. The outcome of the three groups will be analyzed at the end of the study. If required, an interim analysis will be done.

 
Close